Relation with other Networks
EUROmediCAT is a daughter of the EUROCAT (European Surveillance of Congenital Anomalies) network of population-based registers for the epidemiological surveillance of congenital anomalies.The potential for conducting post marketing surveillance within the EUROCAT network was first shown by the EUROCAT AntiEpileptic Study Working Group, which created a dedicated database in 2007 and included data from 19 registries, 1995-2005. This dataset was used to conduct a case-control study evaluating the risk of orofacial clefts in relation to lamotrigine exposure (Dolk 2008), recently updated, and studies related to Valproic Acid (Jentink, 2010) and Carbamazepine (Jentink, 2010).
EUROmediCAT builds on
- the EUROCAT database, enriched with detailed data on prescribing and dispensing drugs in pregnancy.
- the EUROCAT network, enriched with a broader network of expertise on drug safety.
More information on the EUROCAT network can be found on the EUROCAT website
A number of the institutions involved in EUROmediCAT are member of the European Network of Centres for Pharmacoepidemiology and Pharmcovigilance (ENCePP).
The ENCePP scientific network is coordinated by the European Medicines Agency. It’s members are dedicated to excellence in research by adhering to the ENCePP Guide on Methodological Standards and promoting scientific independence and transparency.
The EUROmediCAT study is registered in the EncePP E-Register of Studies, a publicly accessible resource for the registration of pharmacoepidemiological and pharmacovigilance studies.